{"id":105477,"date":"2018-10-22T17:30:05","date_gmt":"2018-10-22T17:30:05","guid":{"rendered":"http:\/\/news.alabamanewsreporter.com\/story\/105477\/diabetes-drug-market-by-oral-dpp-iv-inhibitor-sglt2-biguanide-etc-injection-glp-amylin-receptor-agonist-etc-insulin-rapid-long-acting-premixed-insulin-regions-companies.html"},"modified":"2018-10-22T17:30:05","modified_gmt":"2018-10-22T17:30:05","slug":"diabetes-drug-market-by-oral-dpp-iv-inhibitor-sglt2-biguanide-etc-injection-glp-amylin-receptor-agonist-etc-insulin-rapid-long-acting-premixed-insulin-regions-companies","status":"publish","type":"post","link":"https:\/\/www.alaskanewsdesk.com\/news\/story\/105477\/diabetes-drug-market-by-oral-dpp-iv-inhibitor-sglt2-biguanide-etc-injection-glp-amylin-receptor-agonist-etc-insulin-rapid-long-acting-premixed-insulin-regions-companies.html","title":{"rendered":"Diabetes Drug Market, by Oral (DPP IV Inhibitor, SGLT-2, Biguanide, etc) Injection (GLP, Amylin Receptor Agonist, etc), Insulin (Rapid, Long Acting, Premixed Insulin), Regions & Companies"},"content":{"rendered":"
\"\"<\/a><\/p>\n
\n
Global diabetes drug market is expected to surpass US$ 76 Billion by the end of year 2024. Rising global diabetes prevalence like Type 1 diabetes and Type 2 diabetes is the major reason for growth of diabetes drug market.<\/div>\n<\/div>\n<\/div>\n
Renub Research report titled \u201cDiabetes Drug Market, Oral (DPP IV Inhibitor, SGLT-2, Alpha Glucosidase Inhibitor, Biguanide) Injection (Glucagon-like peptide (GLP) 1 agonist, Amylin Receptor Agonist), Insulin (Rapid \u2013 Acting Insulin, Long Acting Insulin, Premixed Insulin), Regions (United States, Europe, Japan, China, India, Brazil), Companies (Novo Nordisk, Merck & Co, Eli Lilly, AstraZeneca, Johnson & Johnson, Boehringer Ingelheim)\u201d provides a complete analysis of Diabetes Drug Market.<\/div>\n

Global diabetes drug market is expected to surpass US$ 76 Billion<\/strong> by the end of year 2024<\/strong>. Rising global diabetes prevalence like Type 1 diabetes and Type 2 diabetes is the major reason for growth of diabetes drug market. Type 2 diabetes is on the rise globally due to growth in obesity trends, sedentary lifestyle and lack of physical activity. Type1 diabetes patient requires less amount diabetes drug, whereas Type 2 diabetes patient are massive consumer of diabetes drug. Several companies are creating their diabetes drug pipeline and trying to broaden their diabetes drug portfolio which will further boost the global diabetes drug market<\/strong><\/a> in forecast period.<\/p>\n

Diabetes is condition in which the patient has a high blood sugar level over a long drawn period. There are 3 types of diabetes Type 1 diabetes, Type 2 diabetes and Gestational diabetes. Type 1 diabetes is a condition in which patient pancreas fail to produce enough insulin. It is also called juvenile diabetes. In Type 2 diabetes body cells fails to respond to insulin properly. Third one is Gestational diabetes in which a pregnant woman with no history of diabetes develops high blood sugar level. Globally 90% of the diabetes patients are Type 2 and rest are Type 1 cases.<\/p>\n

Request a free sample copy of the report: https:\/\/www.renub.com\/contactus.php<\/a><\/strong><\/p>\n

Renub Research report titled “Diabetes Drug Market, Oral (DPP IV Inhibitor, SGLT-2, Alpha Glucosidase Inhibitor, Biguanide) Injection (Glucagon-like peptide (GLP) 1 agonist, Amylin Receptor Agonist), Insulin (Rapid – Acting Insulin, Long Acting Insulin, Premixed Insulin), Regions (United States, Europe, Japan, China, India, Brazil), Companies (Novo Nordisk, Merck & Co, Eli Lilly, AstraZeneca, Johnson & Johnson, Boehringer Ingelheim)” provides a complete analysis of Diabetes Drug Market.<\/p>\n

 <\/p>\n

Type 2 Diabetes Patients has bigger Consumer Base<\/strong><\/p>\n

In this report, we have categorized the diabetes drug market into two part; type 1 diabetes drug market and type 2 diabetes drug markets.<\/p>\n

(DPP) IV Inhibitor Segment has the largest Market in Global Diabetes Drug Market<\/p>\n

According to Renub Research this report provides in-depth analysis of diabetes drug market form multiple perspectives. Here the global diabetes drug market has been categorized into 3 segments: Oral Diabetes Drug Market, Injectable Diabetes Drug Market and Insulin.<\/p>\n

Oral Diabetes Drug Market is further sub-divided into 5 categories by drug class- (DPP) IV Inhibitor, SGLT-2, Alpha Glucosidase Inhibitor, Biguanide and Other Oral Drug market.<\/p>\n

Injectable Diabetes Drug Market has been further classified into 2 parts – Glucagon-like peptide (GLP) 1 agonist and Amylin receptor agonist market.<\/p>\n

Insulin Market has been further categorized into 4 parts – Rapid – Acting Insulin market, Long Acting Insulin market, Premixed Insulin market and Other Insulin market.<\/p>\n

 <\/p>\n

              \"\"<\/p>\n

United States dominates the Global diabetes drug Market<\/strong><\/p>\n

The regions covered in the report for of type 1 diabetes drug market are United States, European Union (France, Germany, Italy, Spain and United Kingdom), Japan and Canada.<\/p>\n

The regions covered for type 2 diabetes drug market – are United States, European Union (France, Germany, Italy, Spain and United Kingdom), Japan, China, India and Brazil. In addition, we have also covered diabetes population of each of these covered regions along with Type 1 and Type 2 diabetes populations.<\/p>\n

Novo Nordisk is the Largest Player in Global Diabetes Drug Market<\/strong><\/p>\n

In this report, published by Renub Research a comprehensive assessment of global diabetes drug revenue by five major key players is covered. The key players covered in the report are Novo Nordisk, Merck & Co, Eli Lilly, AstraZeneca, Johnson & Johnson and Boehringer Ingelheim. This report covers historical sales analysis and forecast along with major factors like diabetes R&D and pipeline of diabetes drug in separate chapter.<\/p>\n

 <\/p>\n

Client can Purchase this Report in Sections<\/strong> from below link:<\/p>\n

Access full Research:  https:\/\/www.renub.com\/diabetes-drug-market-p.php<\/a><\/strong><\/p>\n

Disease Type – Global Diabetes Drug Market<\/strong><\/p>\n

1. By Type 1 Diabetes Drug Market
2. By Type 2 Diabetes Drug Market<\/p>\n

 <\/p>\n

Product – Global Diabetes Drug Market<\/strong><\/p>\n

Oral<\/strong><\/p>\n

1. (DPP) IV inhibitor
2. SGLT-2
3. Alpha Glucosidase Inhibitor
4. Biguanide
5. Others Oral Drug<\/p>\n

Injection<\/strong><\/p>\n

1. Glucagon-like peptide (GLP) 1 agonist
2. Amylin receptor agonist<\/p>\n

Insulin<\/strong><\/p>\n

1. Rapid – Acting Insulin
2. Long Acting Insulin
3. Premixed Insulin
4. Other Insulin<\/p>\n

 <\/p>\n

Regions – Population Type 1 & Type 2 Diabetes Drug<\/strong><\/p>\n

1. United States
2. 5 European Union (France, Germany, Italy, Spain and United Kingdom)
3. Japan
4. China
5. India
6. Brazil<\/p>\n

Regions – Type 1 Diabetes Drug Market<\/strong><\/p>\n

1. United States
2. 5 European Union (France, Germany, Italy, Spain and United Kingdom)
3. Japan
4. Canada<\/p>\n

Regions – Type 2 Diabetes Drug Market<\/strong><\/p>\n

1. United States
2. 5 European Union (France, Germany, Italy, Spain and United Kingdom)
3. Japan
4. China
5. India
6. Brazil<\/p>\n

Key Players Analysis<\/strong><\/p>\n

1. Novo Nordisk
2. Merck & Co
3. Eli Lilly
4. AstraZeneca
5. Johnson & Johnson
6. Boehringer Ingelheim<\/p>\n

If the information you seek is not included in the current scope of the study kindly share your specific requirements with our custom research team at info@renub.com<\/p>\n

 <\/p>\n

Browse Related Report :<\/strong><\/p>\n

Global CGM Market<\/strong><\/a><\/p>\n

Insulin Pump Market<\/a><\/p>\n

 <\/p>\n

Contact Us<\/strong><\/p>\n

Renub Research<\/strong><\/p>\n

Phone:<\/strong>+1-678-302-0700<\/p>\n

Email:<\/strong> info@renub.com<\/p>\n

 <\/p>\n

Key Topics Covered:<\/strong><\/p>\n

1. Introduction<\/strong><\/p>\n

1.1 Market Definition
1.2 Currency Conversion<\/p>\n

2. Research Methodology<\/strong><\/p>\n

3. Executive Summary<\/strong><\/p>\n

4. Global Diabetes Drug Market<\/strong><\/p>\n

5. Market Share – Global Diabetes Drug<\/strong><\/p>\n

5.1 Disease Type
5.2 Therapy – (Oral, Injection, Insulin)
5.3 Oral Drug
5.4 Injection Drug
5.5 Insulin
5.6 Regions – Type 1 Diabetes Drug
5.7 Regions – Type 2 Diabetes Drug<\/p>\n

6. Disease Type – Global Diabetes Drug Market<\/strong><\/p>\n

6.1 Type 1 Diabetes
6.2 Type 2 Diabetes<\/p>\n

7. Therapy – Global Diabetes Drug Market<\/strong><\/p>\n

7.1 Oral Drugs Market
7.2 Injectable Drugs Market
7.3 Insulin Market<\/p>\n

8. Region – Type 1 Diabetes Drug Market<\/strong><\/p>\n

8.1 United States
8.2 European Union
8.3 Japan
8.4 Canada<\/p>\n

9. Region – Type 2 Diabetes Drug Market<\/strong><\/p>\n

9.1 United States
9.2 European Union
9.3 Japan
9.4 China
9.5 India
9.6 Brazil<\/p>\n

10. Regions – Diabetic Population<\/strong><\/p>\n

10.1 United States
10.2 European Union
10.3 Japan
10.4 Canada
10.5 China
10.6 India
10.7 Brazil<\/p>\n

11. Key Players Analysis<\/strong><\/p>\n

11.1 Novo Nordisk Overview
11.2 Merck & Co Overview
11.3 Eli Lilly Overview
11.4 AstraZeneca Overview
11.5 Johnson & Johnson Overview
11.6 Boehringer Ingelheim Overview<\/p>\n

12. Mergers & Acquisitions<\/strong><\/p>\n

13. Market Dynamics<\/strong><\/p>\n

13.1 Growth Drivers
13.2 Challenges
13.3 Opportunities<\/p>\n

 <\/p>\n

About Us<\/strong><\/p>\n

Renub Research is a Market Research and Consulting Company. We have more than 10 years of experience especially in international Business-to-Business Researches, Surveys and Consulting. We provide wide range of business research solutions that helps companies in making better business decisions. Our clients rely on our market analysis and data to make informed knowledgeable decisions. Our pertinent analysis helps consultants, bankers and executives to make informed and correct decisions.<\/p>\n

 <\/p>\n

Media Contact<\/span>
Company Name:<\/strong> Renub Research<\/a>
Contact Person:<\/strong> Rajat Gupta
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> 6783020700
Address:<\/strong>225 Kristie Ln
City:<\/strong> Roswell
State:<\/strong> GA
Country:<\/strong> United States
Website:<\/strong> www.renub.com\/life-science-1-c.php<\/a><\/p>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

Global diabetes drug market is expected to surpass US$ 76 Billion by the end of year 2024. Rising global diabetes prevalence like Type 1 diabetes and Type 2 diabetes is<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"_links":{"self":[{"href":"https:\/\/www.alaskanewsdesk.com\/news\/wp-json\/wp\/v2\/posts\/105477"}],"collection":[{"href":"https:\/\/www.alaskanewsdesk.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.alaskanewsdesk.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.alaskanewsdesk.com\/news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.alaskanewsdesk.com\/news\/wp-json\/wp\/v2\/comments?post=105477"}],"version-history":[{"count":0,"href":"https:\/\/www.alaskanewsdesk.com\/news\/wp-json\/wp\/v2\/posts\/105477\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.alaskanewsdesk.com\/news\/wp-json\/wp\/v2\/media?parent=105477"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.alaskanewsdesk.com\/news\/wp-json\/wp\/v2\/categories?post=105477"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.alaskanewsdesk.com\/news\/wp-json\/wp\/v2\/tags?post=105477"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}